Pfizer is facing another setback with its weight-loss pill, danuglipron. The pharmaceutical giant stopped development of the ...

Pfizer's strong R&D pipeline, 7.5%+ dividend yield, & undervalued PE ratio make PFE stock a compelling investment opportunity ...

Pfizer stock shows strong potential with updates on danuglipron, robust cost controls, and attractive valuations. Learn more ...

A majority of Americans believe President Trump's tariffs will, at least in the short-term, raise prices, according to a new ...

Pharmaceutical companies are worried about the threat of tariffs and what they would mean for investment in Europe, the Chief ...

President Trump unveiled a wide-ranging executive order that aims to lower drug prices, boost transparency into fees charged ...

Viatris said on Monday it would pay up to $335 million over nine years as part of a nationwide settlement to resolve claims ...

Buying stock in great companies when they are dealing with some short-term issue that creates stock price weakness ... as investors appear to be doubtful that Pfizer's growth strategy will pay off.

This attention to innovation began to pay ... Pfizer $12 billion a year in 2007, one quarter of its total sales. It almost hadn’t made it through clinical development, facing problems with ...

In an interview, the US pharmaceuticals giant’s international chief says Australia has made no progress in making life easier for medicine developers.

Sustainabilitycategory· April 15, 2025 European pharma companies issue demands to stay in EU ... Healthcare & Pharmaceuticalscategory· April 14, 2025 Pfizer ends development of weight-loss ...